WO2001000824A3 - PROTEINES HUMAINES A DOMAINES HYDROPHOBES ET ADNs LES CODANT - Google Patents

PROTEINES HUMAINES A DOMAINES HYDROPHOBES ET ADNs LES CODANT Download PDF

Info

Publication number
WO2001000824A3
WO2001000824A3 PCT/JP2000/003944 JP0003944W WO0100824A3 WO 2001000824 A3 WO2001000824 A3 WO 2001000824A3 JP 0003944 W JP0003944 W JP 0003944W WO 0100824 A3 WO0100824 A3 WO 0100824A3
Authority
WO
WIPO (PCT)
Prior art keywords
proteins
hydrophobic domains
dnas encoding
dnas
human
Prior art date
Application number
PCT/JP2000/003944
Other languages
English (en)
Other versions
WO2001000824A2 (fr
Inventor
Seishi Kato
Tomoko Kimura
Original Assignee
Sagami Chem Res
Protegene Inc
Seishi Kato
Tomoko Kimura
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sagami Chem Res, Protegene Inc, Seishi Kato, Tomoko Kimura filed Critical Sagami Chem Res
Priority to AU52499/00A priority Critical patent/AU5249900A/en
Priority to EP00937279A priority patent/EP1194543A2/fr
Priority to JP2001506817A priority patent/JP2003503054A/ja
Publication of WO2001000824A2 publication Critical patent/WO2001000824A2/fr
Publication of WO2001000824A3 publication Critical patent/WO2001000824A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Cell Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)

Abstract

La présente invention concerne des protéines humaines à domaines hydrophobes, des ADN codant ces protéines, des vecteurs d'expression pour ces ADN, des cellules eucaryotes transformées exprimant ces ADN, et des anticorps dirigés contre ces protéines.
PCT/JP2000/003944 1999-06-24 2000-06-16 PROTEINES HUMAINES A DOMAINES HYDROPHOBES ET ADNs LES CODANT WO2001000824A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU52499/00A AU5249900A (en) 1999-06-24 2000-06-16 Human proteins having hydrophobic domains and dnas encoding these proteins
EP00937279A EP1194543A2 (fr) 1999-06-24 2000-06-16 PROTEINES HUMAINES A DOMAINES HYDROPHOBES ET ADNs LES CODANT
JP2001506817A JP2003503054A (ja) 1999-06-24 2000-06-16 疎水性ドメインを有するヒトプロテイン及びそれをコードするｄｎａ

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP17806599 1999-06-24
JP11/178065 1999-06-24

Publications (2)

Publication Number Publication Date
WO2001000824A2 WO2001000824A2 (fr) 2001-01-04
WO2001000824A3 true WO2001000824A3 (fr) 2001-07-05

Family

ID=16042010

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2000/003944 WO2001000824A2 (fr) 1999-06-24 2000-06-16 PROTEINES HUMAINES A DOMAINES HYDROPHOBES ET ADNs LES CODANT

Country Status (4)

Country Link
EP (1) EP1194543A2 (fr)
JP (1) JP2003503054A (fr)
AU (1) AU5249900A (fr)
WO (1) WO2001000824A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4344519B2 (ja) * 2000-12-28 2009-10-14 旭化成ファーマ株式会社 ＮＦ−κＢ活性化遺伝子

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998021328A2 (fr) * 1996-11-13 1998-05-22 Sagami Chemical Research Center Proteines humaines possedant des domaines de transmembrane et adn codant ces proteines
WO1999018126A1 (fr) * 1997-10-07 1999-04-15 Ono Pharmaceutical Co., Ltd. POLYPEPTIDE, ADNc LE CODANT ET LEUR UTILISATION
WO1999031236A2 (fr) * 1997-12-17 1999-06-24 Genset ADNc PROLONGES POUR PROTEINES SECRETEES

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998021328A2 (fr) * 1996-11-13 1998-05-22 Sagami Chemical Research Center Proteines humaines possedant des domaines de transmembrane et adn codant ces proteines
WO1999018126A1 (fr) * 1997-10-07 1999-04-15 Ono Pharmaceutical Co., Ltd. POLYPEPTIDE, ADNc LE CODANT ET LEUR UTILISATION
WO1999031236A2 (fr) * 1997-12-17 1999-06-24 Genset ADNc PROLONGES POUR PROTEINES SECRETEES

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
D'ANDREA ET AL: "Molecular Cloning of NKB1. A Natural Killer Cell Receptor for HLA-B Allotypes", JOURNAL OF IMMUNOLOGY,US,THE WILLIAMS AND WILKINS CO. BALTIMORE, vol. 155, no. 5, 1 September 1995 (1995-09-01), pages 2306 - 2310, XP002111500, ISSN: 0022-1767 *
DATABASE EMBL EBI; 16 April 1998 (1998-04-16), STRAUSBERG: "National cancer institute, Cancer genome anatomy project", XP002151124 *
DATABASE EMBL EBI; 25 September 1996 (1996-09-25), HILLIER ET AL.: "Generation and analysis of 280,000 human expressed sequence tags", XP002151123 *
DATABASE EMBL EBI; 9 April 1999 (1999-04-09), NAGASE ET AL.: "Homo sapiens mRNA for KIAA1007, partial cds.", XP002151125 *
DATABASE WPI Section Ch Week 199923, Derwent World Patents Index; Class B04, AN 1999-277254, XP002151126 *
GILLEN C M ET AL: "Molecular cloning and functional expression of the K-Cl cotransporter from rabbit, rat, and human", JOURNAL OF BIOLOGICAL CHEMISTRY,US,AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, vol. 271, no. 27, 5 July 1996 (1996-07-05), pages 16237 - 16244, XP002119528, ISSN: 0021-9258 *
KYTE J ET AL: "A SIMPLE METHOD FOR DISPLAYING THE HYDROPATHIC CHARACTER OF A PROTEIN", JOURNAL OF MOLECULAR BIOLOGY,GB,LONDON, vol. 157, no. 1, 5 May 1982 (1982-05-05), pages 105 - 132, XP000609503, ISSN: 0022-2836 *
NAGASE ET AL.: "Prediction of the coding sequences of unidentified human genes. XIII. The complete sequences of 100 new cDNA clones from brain which code for large proteins in vitro", DNA RESEARCH, vol. 6, 26 February 1999 (1999-02-26), pages 63 - 70, XP000952912 *

Also Published As

Publication number Publication date
JP2003503054A (ja) 2003-01-28
EP1194543A2 (fr) 2002-04-10
AU5249900A (en) 2001-01-31
WO2001000824A2 (fr) 2001-01-04

Similar Documents

Publication Publication Date Title
WO2001049728A3 (fr) Proteines humaines a domaines hydrophobes et adn codant ces proteines
WO2000005367A3 (fr) Proteines humaines a domaines hydrophobes et adn codant pour ces proteines
WO2001012660A3 (fr) Proteines humaines a domaines hydrophobes et adn codant pour ces proteines
WO2000029448A3 (fr) Proteines humaines a domaines hydrophobes et adn codant pour ces proteines
AU4189799A (en) Prostate growth-associated membrane proteins
NO20016243D0 (no) Anti-alfav-beta3-rekombinante humane antistoffer, nukleinsyrer som koder for de samme og fremgangsmåter foranvendelse
AU1462300A (en) Human pan-hcv human monoclonal antibodies
WO2001002563A3 (fr) Proteines humaines ayant des domaines hydrophobes et adn codant pour ces proteines
EP1571216A3 (fr) Phosphodiestérase 8A
WO2002059315A3 (fr) Nouveaux acides nucleiques et polypeptides et procedes de leur utilisation
WO2000069884A3 (fr) Compositions isolees a partir de cellules cutanees, et leurs procedes d'utilisation
WO2002036627A3 (fr) Interferons, utilisations et compositions associees
MXPA01003868A (es) Apomixis conferida por la expresion de proteinas que interactuan con la cinasa receptora de embriogenesis somatica.
WO1999049038A3 (fr) Proteines de fixation du calcium humaines
HUP0103152A2 (hu) G3BP fehérje elleni monoklonális antitestek és alkalmazásuk
WO2001004297A3 (fr) Proteines humaines a domaines hydrophobes et adn codant ces proteines
WO1999009182A3 (fr) Proteines rab
WO2001000824A3 (fr) PROTEINES HUMAINES A DOMAINES HYDROPHOBES ET ADNs LES CODANT
AU2452301A (en) Protein methylarginine-specific antibodies
ZA99677B (en) Placental protein 13.
WO2001088137A3 (fr) Proteines du type proteine adaptatrice myd88
WO2000000506A3 (fr) Proteines humaines possedant des domaines hydrophobes et adn codant ces proteines
AU7478098A (en) Methods of treatment using nbs-1, antibodies and proteins thereto, and uses of the antibodies
WO2000019210A3 (fr) REACTIFS BIOLOGIQUES ET PROCEDES SERVANT A DETERMINER LE MECANISME IMPLIQUE DANS LA GENERATION DU PEPTIDE β-AMYLOIDE
AU3452700A (en) Antibodies to placental protein 13

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 506817

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2000937279

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000937279

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 200208527

Country of ref document: ZA

WWW Wipo information: withdrawn in national office

Ref document number: 2000937279

Country of ref document: EP